Full Press Release Details
British Columbia Securities Commission
Alberta Securities Commission
Ontario Securities Commission
RE: ESSA Pharma Inc.
Re: Prospectus Supplement dated April
15, 2016 to the Short Form Base Shelf Prospectus dated December 22, 2015
We refer to the prospectus supplement of
ESSA Pharma Inc. ("ESSA") dated April 15, 2016 (the "Prospectus Supplement") to the short
form base shelf prospectus of ESSA dated December 22, 2015 (together with the Prospectus Supplement, the "Supplemented
We hereby consent to the reference to our
name and inclusion of our opinion under the headings "Certain Canadian Federal Income Tax Considerations" and "Eligibility
for Investment" and the reference to our name under the heading "Legal Matters" in the Prospectus Supplement.
We confirm that we have read the Supplemented
Prospectus and that we have no reason to believe that there are any misrepresentations in the information contained in the Supplemented
Prospectus that are derived from our opinion referred to above or that are within our knowledge as a result of services we performed
in connection with the preparation of such opinion.
This letter is delivered to the addressees
pursuant to the requirements of Section 4.2(a)(vii) of National Instrument 44-101 - Short Form Prospectus Distributions
and Section 7.2(1) of National Instrument 44-102 - Shelf Distributions.
(Signed) Blake, Cassels & Graydon LLP